Saturday 17 October 2026
Export ROIV’s income statement to Excel — free account
Roivant Sciences Ltd.
ROIV Healthcare Biotechnology
In the quarter to June 2026, revenue fell 33.6%, EPS grew 21.2% and free cash flow fell 30.0%, each against the same quarter a year earlier.
33.53
0.51
−1.50%
Follow ROIV
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
506.80 | 1,136.13 | 2,326.88 | 3,386.66 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(55.49) | (76.96) | (117.33) | (94.30) | |
P/B ratio |
2.14 | 3.04 | 3.63 | 5.18 | |
Price to Tangible BV |
2.21 | 3.13 | 3.73 | 5.33 | |
EV/Sales |
306.98 | 820.11 | 1,846.48 | 2,919.53 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.11) | (14.38) | (20.33) | (26.93) | |
EV/FCF |
(7.96) | (14.23) | (20.11) | (26.78) | |
Quick Ratio |
32.77 | 29.81 | 18.00 | 16.27 | |
Current Ratio |
33.71 | 30.66 | 18.37 | 16.72 | |
Net Debt/EBITDA |
14.37 | 13.38 | (10.32) | 10.51 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.64 | 0.74 | (0.54) | 1.42 | |
Capex/Depreciation |
(8.52) | 7.14 | (1.98) | (0.70) | |
Research and Development Expense of Revenue |
10,475.37% | 8,273.14% | 7,894.64% | 14,009.43% | |
Selling, General and Administrative Expense of Revenue |
9,110.44% | 8,757.98% | 6,279.76% | 11,478.99% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5,208.21% | 5,252.48% | 3,062.26% | 5,779.61% | |
Graham Net Nets |
0.41 | 0.29 | 0.25 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.70%) | (5.39%) | (1.62%) | (1.07%) | |
Free Cash Flow Yield |
(7.61%) | (5.07%) | (3.95%) | (3.22%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.27) | (0.28) | (0.24) | (0.38) | |
Capex per Share |
(0.01) | 0.01 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.28) | (0.27) | (0.24) | (0.38) | |
Cash per Share |
6.44 | 6.50 | 6.19 | 5.33 | |
Shareholders Equity per Share |
7.06 | 7.14 | 7.63 | 6.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.06 | 7.14 | 7.63 | 6.83 | |
Free Cash Flow |
(193.51) | (191.55) | (165.08) | (270.92) | |
Working Capital |
4,377.79 | 4,507.93 | 4,886.14 | 4,458.48 | |
Capital Expenditures |
(7.85) | 4.94 | (1.26) | (0.42) | |
Net Current Asset Value |
4,254.51 | 4,408.75 | 4,751.11 | 4,357.46 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
5.00 | (2.47) | 0.50 | 0.29 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
20.10 | 18.50 | 20.85 | 18.32 | |
Average Assets |
5,634.31 | 5,508.86 | 5,572.81 | 5,169.55 | |
Average Common Equity |
5,192.75 | 5,255.10 | 5,239.81 | 4,868.89 |
Columns are period end dates · fundamentals updated 1 Oct 2026